Edwards Hedges Bets Between Percutaneous And Surgical Heart Valves
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will continue developing new surgical heart valves, in addition to potentially more lucrative percutaneous valve technologies
You may also be interested in...
Edwards Plans Percutaneous Valve Trials For European, U.S. Market Approval
Edwards Lifesciences' percutaneous aortic valve PMA submission likely will include a randomized trial with 12-month follow-up
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.